BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC".

Cancer Med · 2023 · PMC9939132 · PMID 36208021

Europe PMC DOI

hedged sentences

0.0004

closest p · 0.0× alpha

0.0800

boldest claim

The sentences

highly significantp = 0.0004actually significant

Considering UND patients, we observed a highly significant prevalence in group 1 than in group 2 both at 1 month (83 vs. 16, p = 0.0004) and at 2 months (76 vs. 7, p < 0.0001).

also in 132,142 other papers

did not reach statistical significancep = 0.08so close (0.05 < p ≤ 0.1)

Mean BCR::ABL1 RNA expression at drug discontinuation for groups 1 and 2 was 0.0010 ± 0.0020 and 0.0018 ± 0.0029, respectively ( p = 0.052); difference in molecular response at stop did not reach statistical significance neither in the imatinib cohort (group 1: 0.0007 ± 0.0019, group 2: 0.0016 ± 0.0026; p = 0.08) nor in the 2G‐TKI‐treated patients (group 1: 0.0015 ± 0.0023, group 2: 0.0022 ± 0.0032; p = 0.64).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.